Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in TG Therapeutics, Inc. or Qiagen N.V. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how TG Therapeutics, Inc. and Qiagen N.V. compare based on key financial metrics to determine which better meets your investment needs.

About TG Therapeutics, Inc. and Qiagen N.V.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Latest Biotechnology and TG Therapeutics, Inc., Qiagen N.V. Stock News

As of July 30, 2026, TG Therapeutics, Inc. had a $7.6 billion market capitalization, compared to the Biotechnology median of $251.9 million. TG Therapeutics, Inc.’s stock is up 74.5% in 2026, down 7.2% in the previous five trading days and up 51.32% in the past year.

Currently, TG Therapeutics, Inc.’s price-earnings ratio is 18.6. TG Therapeutics, Inc.’s trailing 12-month revenue is $700.3 million with a 66.0% net profit margin. Year-over-year quarterly sales growth most recently was 69.5%. Analysts expect adjusted earnings to reach $1.572 per share for the current fiscal year. TG Therapeutics, Inc. does not currently pay a dividend.

As of July 30, 2026, Qiagen N.V. had a $8.6 billion market cap, putting it in the 75th percentile of all stocks. Qiagen N.V.’s stock is down 12.5% in 2026, up 0.1% in the previous five trading days and down 22.9% in the past year.

Currently, Qiagen N.V.’s price-earnings ratio is 21.4. Qiagen N.V.’s trailing 12-month revenue is $2.1 billion with a 19.2% net profit margin. Year-over-year quarterly sales growth most recently was 1.8%. Analysts expect adjusted earnings to reach $2.440 per share for the current fiscal year. Qiagen N.V. currently has a 5.8% dividend yield.

How We Compare TG Therapeutics, Inc. and Qiagen N.V. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at TG Therapeutics, Inc. and Qiagen N.V.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

TG Therapeutics, Inc. and Qiagen N.V. Growth Grades

Company	Ticker	Growth
TG Therapeutics, Inc.	TGTX	F
Qiagen N.V.	QGEN	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

TG Therapeutics, Inc. has a Growth Score of 18, which is Very Weak. Qiagen N.V. has a Growth Score of 56, which is Average.

The Growth Stock Winner: No Clear Winner

Neither TG Therapeutics, Inc. or Qiagen N.V. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if TG Therapeutics, Inc. or Qiagen N.V. is the better investment when it comes to sustainable growth.

TG Therapeutics, Inc. and Qiagen N.V.’s Quality Grades

Company	Ticker	Quality
TG Therapeutics, Inc.	TGTX	C
Qiagen N.V.	QGEN	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

TG Therapeutics, Inc. has a Quality Score of 56, which is Average. Qiagen N.V. has a Quality Score of 80, which is Strong.

The Quality Grade Winner: Qiagen N.V.

As you can clearly see from the Quality Grade breakdown above, Qiagen N.V. has a better overall quality grade than TG Therapeutics, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Qiagen N.V. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

TG Therapeutics, Inc. and Qiagen N.V.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
TG Therapeutics, Inc.	TGTX	C
Qiagen N.V.	QGEN	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

TG Therapeutics, Inc. has a Earnings Estimate Score of 50, which is Neutral. Qiagen N.V. has a Earnings Estimate Score of 30, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither TG Therapeutics, Inc. or Qiagen N.V. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if TG Therapeutics, Inc. or Qiagen N.V. is the better investment when it comes to estimate revisions.

Other TG Therapeutics, Inc. and Qiagen N.V. Grades

In addition to Quality, Estimate Revisions and Growth, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether TG Therapeutics, Inc. and Qiagen N.V. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, TG Therapeutics, Inc. or Qiagen N.V. Stock?

Overall, TG Therapeutics, Inc. stock has a Growth Score of 18, Estimate Revisions Score of 50 and Quality Score of 56.

Qiagen N.V. stock has a Growth Score of 56, Estimate Revisions Score of 30 and Quality Score of 80.

Comparing TG Therapeutics, Inc. and Qiagen N.V.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.